The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early phase clinical trials to evaluate putative neuroprotective therapies in progressive MS. Illustrated by the MSCIMS trial protocol, we describe a novel methodology based on detailed assessment of the anterior visual pathway as a model of wider disease processes--the "sentinel lesion approach". METHODS/DESIGN: MSCIMS is a phase IIA study of autologous mesenchymal stem cells (MSCs) in secondary progressive MS. A pre-test : post-test design is used with healthy controls providing normative data for inter-session variability. Complementary eligibility criteria and outcomes are used to select participants with disease affecting the anterior visual pathway. RESULTS: Ten participants with MS and eight healthy controls were recruited between October 2008 and March 2009. Mesenchymal stem cells were successfully isolated, expanded and characterised in vitro for all participants in the treatment arm. CONCLUSIONS: In addition to determining the safety and feasibility of the intervention and informing design of future studies to address efficacy, MSCIMS adopts a novel strategy for testing neuroprotective agents in MS--the sentinel lesion approach--serving as proof of principle for its future wider applicability. TRIAL REGISTRATION: ClinicalTrials.gov (NCT00395200).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hobart, J. C., Cano, S. J., Zajicek, J. P., & Thompson, A. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70290-9 · Cited by 495
Self-citation
Cited by
Clinical Trials with Mesenchymal Stem Cells: An Update
Squillaro, T., Peluso, G., & Galderisi, U. (2016) · Cell Transplantation · doi:10.3727/096368915x689622 · Cited by 1,395
Mesenchymal stem cells and immunomodulation: current status and future prospects
Gao, F., Chiu, S. M., Motan, D. A. L., Zhang, Z., Chen, L., Ji, H.-L., Tse, H.-F., Fu, Q.-L., & Lian, Q. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.327 · Cited by 1,121
Mesenchymal stem cells: a new trend for cell therapy
Wei, X., Yang, X., Han, Z.-P., Qu, F.-F., Shao, L., & Shi, Y.-F. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.50 · Cited by 942
Connick, P., Kolappan, M., Crawley, C., Webber, D. J., Patani, R., Michell, A. W., Du, M.-Q., Luan, S.-L., Altmann, D. R., Thompson, A. J., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70305-2 · Cited by 607
Self-citationMesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application
Wang, M., Yuan, Q., & Xie, L. (2018) · Stem Cells International · doi:10.1155/2018/3057624 · Cited by 505
Metadata
- Authors
- Connick, P., Kolappan, M., Patani, R., Scott, M. A., Crawley, C., He, X.-L., Richardson, K., Barber, K., Webber, D. J., Wheeler-Kingshott, C. A., Tozer, D. J., Samson, R. S., Thomas, D. L., Du, M.-Q., Luan, S. L., Michell, A. W., Altmann, D. R., Thompson, A. J., Miller, D. H., Compston, A., & Chandran, S.
- Venue
- Trials
- Published
- 2011-03-02
- Volume
- 12
- Issue
- 1
- Pages
- 62-62
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2108538059
- Cited by
- 119
- References
- 1
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. https://app.cochat.ai/papers/10.1186/1745-6215-12-62
- The paper
- Connick, P., Kolappan, M., Patani, R., Scott, M. A., Crawley, C., He, X.-L., Richardson, K., Barber, K., Webber, D. J., Wheeler-Kingshott, C. A., Tozer, D. J., Samson, R. S., Thomas, D. L., Du, M.-Q., Luan, S. L., Michell, A. W., Altmann, D. R., Thompson, A. J., Miller, D. H., . . . Chandran, S. (2011). The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials. https://doi.org/10.1186/1745-6215-12-62
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.